Sutro Biopharma (STRO) Earnings Analysis

Sutro Biopharma (STRO) has no confirmed upcoming earnings date. Last quarter (2026-05-14) it missed with EPS -2.94 USD vs -2.32 USD est (-26.7%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -0.08.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does STRO next report earnings?

No confirmed upcoming earnings date is currently scheduled for STRO. This page updates as the calendar is published.

STRO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-2.94 USD-2.32 USD-26.7%Miss
2026-03-23-5.29 USD-8.16266 USD+35.2%Beat
2025-11-06-6.7 USD-4.2 USD-59.5%Miss
2025-08-07-0.14 USD-0.39 USD+64.1%Beat
2025-03-13-0.89 USD-0.86 USD-3.5%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

STRO valuation and analyst view

Trailing P/E-0.08
Trailing EPS-1,174.12076 USD
Price / book-0.05
Dividend yield0.00%
Market cap0.23B
Analyst consensusBuy (18 buy / 1 hold / 1 sell)
Avg price target51.5 USD

Related research pages

Frequently asked questions

When is Sutro Biopharma (STRO)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for STRO. This page updates as the calendar is published.

Did STRO beat earnings last quarter?

In its 2026-05-14 report, STRO posted EPS of -2.94 USD versus a -2.32 USD estimate — a miss of 26.7%.

What is STRO's earnings track record?

Over the last 5 reported quarters with consensus data, STRO beat estimates 2 times (40%).

What is STRO's current P/E ratio and EPS?

STRO trades at a trailing P/E of -0.08 on trailing EPS of -1174.1207585822065 USD.

What do analysts rate STRO?

Analyst consensus is "Buy" across 20 ratings (0 strong buy, 18 buy, 1 hold, 1 sell, 0 strong sell). Average 12-month price target: 51.5 USD.